Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Miraca Holdings Inc.    4544   JP3822000000

MIRACA HOLDINGS INC.

(4544)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Sales forecast by analysts have been recently revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • The company does not generate enough profits, which is an alarming weak point.
  • The group usually releases earnings worse than estimated.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
MIRACA HOLDINGS INC.2.74%1 428
GUARDANT HEALTH, INC.4.33%7 655
GENSCRIPT BIOTECH CORPORATI..-1.69%4 214
IOVANCE BIOTHERAPEUTICS, IN..-17.99%2 865
-
INVITAE CORPORATION14.69%1 786
VERACYTE, INC.2.31%1 395
CAREDX, INC0.37%919
SEEGENE INC--.--%728
INNATE PHARMA12.58%582
LYSOGENE184.30%77
EPIGENOMICS AG2.20%67
More Results
Financials (JPY)
Sales 2020 190 B
EBIT 2020 12 986 M
Net income 2020 6 618 M
Debt 2020 29 039 M
Yield 2020 4,73%
P/E ratio 2020 23,7x
P/E ratio 2021 19,8x
EV / Sales2020 0,98x
EV / Sales2021 1,00x
Capitalization 157 B
Upcoming event on MIRACA HOLDINGS INC.
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus -
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes